ClinicalTrials.gg
RecruitingNCT05968118Updated Aug 1, 2023

Angiogenesis and Blood Perfusion Effect of HGF Gene Therapy in PAD Patients

A Phase 3 interventional study of NL003 and Placebo in Peripheral Artery Disease, sponsored by Beijing Northland Biotech. Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-08-01.

Sponsored by Beijing Northland Biotech. Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2023, 3 years 3 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Jul 2022, registered Jan 2023).
  • Started Jul 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Peripheral Arterial Disease with a site in China — 32 open to participants now, 34 under way, 4 of them phase 3. Peripheral Arterial Disease · China.

Planned enrollment
49th of 53
36 · median 167
Started
2022
with 7 others
Phase 3
10 of 80
3 open now
Primary completion
2023-07
later than 0 of 33 live
Registered
52nd of 80
by date
Lead sponsor
2 of 80
Beijing Northland Biotech. Co., Ltd.

Among the 80 studies in Peripheral Arterial Disease with a site in China, this one is the 49th largest by planned enrollment of the 53 interventional ones that give a count, is one of 8 that started in 2022, is one of 10 in phase 3, reaches primary completion later than 0 of the 33 other live ones, and was the 52nd registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

32 of the 80 studies in Peripheral Arterial Disease with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Peripheral Arterial Disease with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether PET/CT-RGD or MIBI can be used for the angiogenesis assessment of NL003 in PAD patients.

Read the detailed description

Hepatocyte growth factor (HGF) gene therapy has been shown to be a potential choice for CLI patients without surgical option. NL003, which is a DNA plasmid that contains novel genomic cDNA hybrid human HGF coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723. Animal studies showed that NL003 inducing angiogenesis in the affected limb and result in an increase in tissue perfusion. Our previous phase II clinical trial has suggested the successful limb-salvaging capacity of NL003 in treatment of patients with CLTI.

In this study we will use 68Ga RGD PET/CT and 99mTc MIBI SPECT imaging methods to evaluate the effect of NL003 on angiogenesis and lower limb blood flow perfusion during the treatment of chronic lower limb ischemia, and evaluated the effectiveness and safety of the drug. The subjects will be randomly divided into the investigational drug group and the placebo group in a 1:1 ratio. NL003 or placebo will be injected into the muscle of the affected limb on D0, D14 and D28, 0.5mg/0.5mL/site, total 8mg, 32 sites. PET/CT will be measured on D14, D42 before drug administration, MIBI SPECT imaging will be collected on D60.

03

Conditions studied

  • Peripheral Artery Disease

Keywords

  • Peripheral Artery Disease
  • Hepatocyte Growth Factor
  • NL003
  • Gene therapy
  • PET/CT-RGD
  • MIBI
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-80 years, diagnosed with chronic lower limb ischemia;
  2. According to DSA or CTA,severe stenosis (≥70%) or occlusion of one or more branches of superficial femoral artery, popliteal artery, anterior tibial artery, posterior tibial artery, and peroneal artery.
  3. Patients with obvious symptoms of lower limb ischemia, including severe claudication, resting pain, ulcers, or gangrene.
  4. Agree to use appropriate methods during the trial; Female subjects of reproductive age, blood pregnancy test negative.
  5. Signing the .
  6. Can complete PETCT-RGD check and MIBI check;

Exclusion criteria

Exclusion Criteria:

  1. The foot or lower limb infection cannot be controlled, and amputation may be accepted within 3 months.
  2. Those with cerebral infarction, cerebral hemorrhage, heart failure, unstable angina, acute myocardial infarction, and serious arrhythmia within 3 months;
  3. Tumor patients diagnosed with malignant tumor or suspected of having malignant tumor after tumor screening;
  4. Main iliac artery stenosis ≥ 70%;
  5. hypertension (taking three or more antihypertensive drugs, systolic blood pressure ≥ 180mmHg or diastolic blood pressure ≥ 110mmHg);
  6. Anti antibody positive person, anti antibody positive person and RNA positive person, surface antigen positive person (if the subject is HBsAg positive, and judging by peripheral blood HBV DNA, the researcher believes that the subject is in a stable period of chronic hepatitis B, which will not increase the risk of the subject, the subject can be selected)
  7. Patients with poor blood glucose control after treatment (>10%);
  8. Persons allergic to contrast medium
  9. The investigator believes that the patient's complications affect the evaluation of safety and effectiveness, or the expected survival period is less than 12 months;
  10. Those who regularly drink more than 14 units of alcohol (1 unit=360 mL beer or 45 mL liquor or 150 mL wine with 40% alcohol) or drug abusers within 12 months before signing the form;
  11. Acute lower limb ischemia or acute aggravation of chronic lower limb ischemia;
  12. Those who received vascular reconstruction of the affected limb within 4 weeks before the informed consent form and whose blood supply improved after the operation
  13. Serious liver or kidney disease or severe anemia judged by the investigator;
  14. Those who cannot correctly describe symptoms and emotions;
  15. Those who participated in other clinical trials within 3 months before signing the informed consent form.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    investigational product

    Patients in this treatment group will receive 8mg NL003 respective in D0、14、28

    Drug: NL003

  • Placebo comparator
    Placebo

    Patients in this group will receive normal saline respective in D0、14、28

    Drug: Placebo

Interventions

  • DrugNL003

    Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)

    Also known as: HGF plasmid, pCK-HGF-X7

  • DrugPlacebo

    Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections ) Other Name: Placebo

    Also known as: Normal Saline

06

What researchers measure

Primary outcomes

  1. Changes of the new blood vessels number

    changes in the number of new blood vessels measured by PETCT-RGD on D14 and D42, compare with that of the baseline.

    Time frame: Day 14、Day 42

  2. Changes of local blood perfusion

    the changes of local blood perfusion measured by MIBI on D60, compare with that of baseline.

    Time frame: Day 60

Secondary outcomes

  1. Changes to the ABI from the baseline

    Ankle-brachial index (ABI) refers to the ratio of systolic blood pressure of the anterior tibial artery (dorsal foot artery) or posterior tibial artery to the systolic blood pressure of the brachial artery.Participants were tested for ankle-brachial index (ABI).

    Time frame: Day 60

  2. Laser Speckle Imaging changes in blood flow from the baseline

    Laser Speckle Imaging changes in blood flow from the baseline was measured on D60.

    Time frame: Day 60

  3. Changes of pain score from the baseline

    The severity of critical Limb ischemia was assessed by Rutherford grading at screening、D14、D28、D42、D60、D90

    Time frame: Day 14、Day 28、Day 42、Day 60、Day 90

  4. Gangrene /Ulcer changes from the baseline

    Changes in the area of ulcer or gangrene from baseline after use of the study drug

    Time frame: Day 14、Day 28、Day 42、Day 60、Day 90

  5. Changes in quality of life scores from baseline

    The quality of life score questionnaire was conducted to evaluate the subjective perception of Critical Limb Ischemia, including the subjects' perception of quality of life, health, or other aspects of life.

    Time frame: Day 60

07

Study locations

1 of 1 sites recruiting
  • Peking Union Medical College Hospital
    Beijing, Beijing 100032, China
    Recruiting
    • Changwei Liu · Principal investigator
    • Xiao Di · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jul 2023, 12 months after the start.

Of 26 phase 3 interventional studies under Peripheral Arterial Disease, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 58. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2023
First posted
Aug 1, 2023
StartActual
Jul 29, 2022
Primary completionEst.
Jul 31, 2023
CompletionEst.
Oct 31, 2023
Last update
Aug 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05968118
Lead sponsor
Beijing Northland Biotech. Co., Ltd.
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Jul 29, 2022
Primary completion
Jul 31, 2023 (estimated)
Completion
Oct 31, 2023 (estimated)
Last update
Aug 1, 2023

Study contacts

Yue Liu, MM
Contact
liuyue@northland-bio.com
86-10-82890893
Yinjian Sun, MS
Contact
sunyinjian@northland-bio.com
+86-10-82890893

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion